Market Research Logo

Cystic Fibrosis Market in Europe 2015-2019

Cystic Fibrosis Market in Europe 2015-2019

About Cystic Fibrosis

Cystic fibrosis, also known as mucoviscidosis, is a genetically inherited disease. The primary symptoms of cystic fibrosis include high salt content in the sweat, breathing difficulties, secretion of abnormally viscous mucus, respiratory complications, difficulties related to digestion, and growth anomalies. Cystic fibrosis is one of the most common genetic disorders observed in Caucasian children. Rare diseases are those that affect less than 5 patients per 10,000, as defined in the EU by Rare Disease UK. Cystic fibrosis is therefore classified under rare diseases. The incidence of cystic fibrosis varies between populations. It is significantly less common in Asian and African populations compared to Caucasians (people from Europe, North America, and Australasia), with a marked difference between each country in those regions. Precise data regarding the prevalence of cystic fibrosis in Europe is not available, but it is estimated to be 1 in 8,000-10,000 individuals. Cystic fibrosis is a chronic disease and is usually progressive in nature. The onset of cystic fibrosis typically occurs in early childhood or, rarely, at birth. The principal manifestations of cystic fibrosis in patients are chronic bronchitis, pancreatic insufficiency, adolescent diabetes, pancreatitis, male sterility, and very rarely intestinal obstruction or liver cirrhosis. The mortality and morbidity of patients are dependent on the degree of bronchopulmonary involvement.

TechNavio's analysts forecast the Cystic Fibrosis market in Europe to grow at a CAGR of 35.10 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Cystic Fibrosis market in Europe for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic and branded therapies used in the treatment of cystic fibrosis including:

  • Small Molecules
  • Biologics
TechNavio's report, Cystic Fibrosis Market in Europe 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers data from Europe; it also covers the market landscape of the Cystic Fibrosis market in Europe and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.Key Vendors
  • Actavis
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • Novartis
  • Vertex Pharmaceuticals
Other Prominent Vendors
  • Abbott
  • Anthera Pharmaceuticals
  • Arcturus Therapeutics
  • Boehringer Ingelheim
  • Chiesi Farmaceutici
  • Corbus Pharmaceuticals
  • Genzyme
  • Insmed
  • Johnson & Johnson
  • Merck Sharp & Dohme
  • Neovii Biotech
  • Novo Nordisk
  • PharmaSwiss
  • Pharmaxis
  • Proteostasis Therapeutics
  • PTC Therapeutics
  • United Medical
  • Venus Remedies
Market Driver
  • Unmet Needs
  • For a full, detailed list, view our report
Market Challenge
  • High Cost of Treatments
  • For a full, detailed list, view our report
Market Trend
  • Rise in Public Awareness
  • For a full, detailed list, view our report
Key Questions Answered in this Report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?


Press Release

TechNavio Announces the Publication of its Research Report – Cystic Fibrosis Market in Europe 2015-2019

TechNavio recognizes the following companies as the key players in the Cystic Fibrosis Market in Europe: Actavis plc, F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Novartis AG and Vertex Pharmaceuticals Inc.

Other Prominent Vendors in the market are: Abbott, Anthera Pharmaceuticals, Arcturus Therapeutics, Boehringer Ingelheim, Chiesi Farmaceutici, Corbus Pharmaceuticals, Genzyme, Insmed, Johnson & Johnson, Merck Sharp & Dohme, Neovii Biotech, Novo Nordisk, PharmaSwiss, Pharmaxis, Proteostasis Therapeutics, PTC Therapeutics, United Medical and Venus Remedies.

Commenting on the report, an analyst from TechNavio’s team said: “Growing awareness among the medical fraternity, patients, and families of patients is one key trend being witnessed in this market. This increases the number of patients seeking treatment and results in growth in the overall consumption of medicines.”

According to the report, High unmet medical needs are one of the major factors propelling the growth of the market. Current treatment options cannot cure the disease completely and, hence, the resultant mortality rate is high. Therefore, drugs that can cause disease remission in patients are expected to drive the growth of the market.

Further, the report states that high cost of drugs is one of the major challenges restricting the growth of the market. Drugs used for the treatment of cystic fibrosis are expensive and, hence, get a poor response from patients. Patients also tend to withdraw from expensive treatment regimens.

Companies Mentioned

Actavis, F. Hoffmann-La Roche, Gilead Sciences, Novartis, Vertex Pharmaceuticals , Abbott, Anthera Pharmaceuticals, Arcturus Therapeutics , Boehringer Ingelheim , Chiesi Farmaceutici, Corbus Pharmaceuticals, Genzyme, Insmed, Johnson & Johnson ,Merck Sharp & Dohme, Neovii Biotech, Novo Nordisk, PharmaSwiss , Pharmaxis , Proteostasis Therapeutics, PTC Therapeutics, United Medical, Venus Remedies

  • Executive Summary
  • List of Abbreviations
  • Scope of the Report
    • Market Overview
    • Product Offerings
  • Market Research Methodology
    • Market Research Process
    • Research Methodology
      • Table Market Research Methodology
  • Product Profiles
    • Zenpep
      • Colomycin/Colobreathe
      • Pulmozyme
      • Cayston
      • TOBI/TOBI Podhaler
      • Kalydeco
  • Introduction
  • Disease Overview
    • Understanding Cystic Fibrosis
      • Table Snapshot of Cystic Fibrosis
    • Pathophysiology
      • Table Defects Caused by CFTR Gene Mutation
    • Epidemiology
      • Global
        • Table Prevalence of Cystic Fibrosis by Country 2014
        • Table Global Prevalence of Cystic Fibrosis by Country 2014
      • UK
        • Table Prevalence of Cystic Fibrosis in UK 2014-2019
        • Table Age Distribution of Cystic Fibrosis Patients in UK at Death 2013 (years)
        • Table Age Distribution of Cystic Fibrosis Patients in UK by Gender 2013
        • Table Age Distribution of Cystic Fibrosis Patients in UK by Sex 2013
    • Diagnosis
      • Table Diagnosis of Cystic Fibrosis
      • Carrier Testing
      • Antenatal Testing
      • Newborn Screening
      • Other Tests
    • Manifestations of Cystic Fibrosis
      • Table Manifestations of Cystic Fibrosis
    • Economic Burden
      • Table Snapshot of Economic Burden of Cystic Fibrosis
  • Pipeline Portfolio
    • Table Pipeline Snapshot of Drugs for Cystic Fibrosis
  • Market Landscape
    • Market Overview
    • Market Size and Forecast
      • Table Cystic Fibrosis Market in Europe 2014-2019 (US$ million)
    • Five Forces Analysis
  • Market Segmentation by Molecule Type
    • Table Segmentation of Cystic Fibrosis Market in Europe by Molecule Type
    • Biologics
      • Enzymes
    • Small Molecules
      • CFTR Modulators
      • Antibiotics
        • Table Segmentation of Cystic Fibrosis Market in Europe by Molecule Type 2014
  • Market Segmentation by Route of Administration
    • Table Segmentation of Cystic Fibrosis Market in Europe by Route of Administration
    • Topical
    • Oral
    • Parenteral
      • Table Segmentation of Cystic Fibrosis Market in Europe by Route of Administration 2014
  • Market Segmentation by Dosage Form
    • Table Segmentation of Cystic Fibrosis Market in Europe by Dosage Form
    • Solid
    • Liquid
      • Table Segmentation of Cystic Fibrosis Market in Europe by Dosage Form 2014
  • Key Leading Countries
    • UK
    • France
    • Italy
    • Germany
    • Spain
  • Buying Criteria
    • Table Buying Criteria in Cystic Fibrosis Market in Europe 2014
  • Market Growth Drivers
    • Table Growth Drivers of Cystic Fibrosis Market in Europe
  • Drivers and their Impact
    • Table Drivers and their Impact on Cystic Fibrosis Market in Europe by Key Customer Category 2014
  • Market Challenges
    • Table Challenges Faced by Cystic Fibrosis Market in Europe
  • Impact of Drivers and Challenges
  • Market Trends
    • Table Trends in Cystic Fibrosis Market in Europe
  • Trends and their Impact
  • Vendor Landscape
    • Competitive Scenario
      • Key News
      • Mergers and Acquisitions
    • Market Share Analysis 2014
      • Table Cystic Fibrosis Market in Europe: Market Share Analysis 2014
      • Actavis
      • F. Hoffmann-La Roche
        • Table Global Sales of Pulmozyme 2012 and 2013 (US$ million)
        • Table Quarterly Global Sales of Pulmozyme 1994-2008 (US$ million)
        • Table Quarterly Sales of Pulmozyme to Collaborators 1997-2008 (US$ million)
      • Gilead Sciences
      • Novartis
        • Table TOBI Podhaler
        • Table Comparison of YoY Global Sales of TOBI/TOBI Podhaler 2006-2013 (US$ million)
      • Vertex Pharmaceuticals
        • Table Comparison of YoY Global Sales of Kalydeco 2012-2013 (US$ million)
    • Other Prominent Vendors
  • Key Vendor Analysis
    • Actavis
      • Key Facts
      • Business Description
      • Business Segmentation
        • Table Aviation Market in Latin America 2014-2018Business Segmentation 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table Global Commercial Aircraft MRO Market 2015-2019 Business Segmentation by Revenue 2012 and 2013 (US$ million)
      • Sales by Geography
        • Table Actavis : Sales by Geography (in US$ million)
      • Business Strategy
      • Key Information
      • SWOT Analysis
    • F. Hoffmann-La Roche
      • Key Facts
      • Business Overview
      • Business Segmentation
        • Table Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
      • Sales by Geography
        • Table F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
        • Table F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
      • Business Strategy
      • Key Information
      • SWOT Analysis
    • Gilead Sciences
      • Key Facts
      • Business Overview
      • Geographical Segmentation by Revenue 2013
        • Table Gilead Sciences: Geographical Segmentation by Revenue 2013
      • Key Developments
      • SWOT Analysis
    • Novartis
      • Key Facts
      • Business Description
      • Business Segmentation
        • Table Novartis AG: Business Segmentation
      • Revenue by Business Segmentation
        • Table Novartis AG: Revenue by Business Segmentation 2013
      • Revenue Comparison 2012 and 2013
        • Table Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
      • Sales by Geography
        • Table Novartis AG: Revenue by Geographical Segmentation 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
    • Vertex Pharmaceuticals
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2013
        • Table Vertex Pharmaceuticals: Business Segmentation by Revenue 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table Vertex Pharmaceuticals: Business Segmentation by Revenue 2012 and 2013 (US$ million)
      • Geographical Segmentation by Revenue 2013
        • Table Vertex Pharmaceuticals: Geographical Segmentation by Revenue 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
  • Other Reports in this Series

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report